ZHZdenka Hruskova

Zdenka Hruskova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zdenka Hruskova has a total of 383 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission

    by Uwe Jerke, Marieluise Kirchner, Theda Up Bartolomaeus, Lovis Kling, Vojtech Kratky, Zdenka Hruskova, Vladimir Tesar, Kai-Uwe Eckardt, Adrian Schreiber, Sofia Forslund, et al.

    Active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) requires intensive immunosuppressive therapy, but continued treatment beyond remission risks serious harm. Because reliable biomarkers of remission are lacking, clinicians often prolong cost-intensive and toxic therapy unnecessarily. Here, we explore the plasma proteome to identify reliable biomarkers of disease remission in patients with AAV, adjusting for patient characteristics and clinical variables. Applying a two-tiered proteomics strategy that combines global discovery with targeted validation, we identify a protein signature of remission. We then implement the resulting 7-protein panel in a targeted mass spectrometry-based assay and confirm its diagnostic performance in an independent patient cohort. The panel consistently outperforms routine markers such as C-reactive protein and ANCA titer. Our findings suggest that this 7-protein panel provides a starting point for developing a clinical tool to support decision-making, with the potential to reduce treatment-related burden, mitigate toxicity, and lower healthcare costs. More broadly, our confounder-controlled proteomics approach provides a scalable blueprint for biomarker discovery in complex inflammatory diseases.


  • Open Access

    Negative impact of very mild volume overload on the heart function in patients on chronic hemodialysis

    by Kristyna Michalickova, Jan Malik, Anna Valerianova, Zdenka Hruskova, Vladimira Bednarova, Frantisek Lopot, Kristina Buryskova Salajova, Zuzana Hladinova, Tereza Vychodilova, Satu Sinikka Pesickova, et al.

    Heart failure is associated with higher mortality of hemodialysis patients. Fluid overload is a major risk factor for cardiovascular disease in these patients, but it is frequently clinically silent. The optimal assessment of ideal dry weight is still searched for. We hypothesized that even very mild fluid overload would be associated with the left ventricular ejection fraction and on the size of heart chambers. Inclusion visit data of a cohort observation study were analyzed: bioelectrical impedance, echocardiography with hemodynamic estimations and basic laboratory tests. Fluid overload was defined by using the fluid overload/extracellular water index (FO/ECW, relative hydration index) > median value. Moreover, analyses according to FO/ECW quartiles were performed. All these measurements were done within an hour and at least 24 h after the previous hemodialysis. We included 334 patients. FO/ECW median was 7%. Patients with fluid overload had lower left ventricular ejection fraction (median (interquartile range): 53(45-62) vs. 60(56-67)%, p = 0.0002), dilatation of all heart chambers, more pronounced hypertrophy of the left ventricle with higher NTproBNP, significantly lower serum albumin levels and lower body mass. The relationship between the relative hydration index and heart changes was gradual. Fluid overload, as defined by the mild criteria, was associated with a worse ejection fraction, but also with other functional and structural heart changes. Our study demonstrates that in patients on dialysis, even mild (often subclinical) fluid overload is associated with structural and functional heart changes. Early identification of fluid overload with improved methods of volume assessment is thus warranted and especially in lean patients.

  • Open Access

    ANCA-associated vasculitides - diagnostic and therapeutic options

    by Zdenka Hrušková, Vladimír Tesař

    Mezi ANCA-asociovan? vaskulitidy pat?? t?i vz?cn? onemocn?n?, granulomat?za s polyangiitidou, mikroskopick? polyangiitida a eozinofiln? granulomat?za s polyangiitidou. Nej?ast?ji postihuj? org?ny ORL oblasti, pl?ce a ledviny. Stanoven? diagn?z... Mezi ANCA-asociovan? vaskulitidy pat?? t?i vz?cn? onemocn?n?, granulomat?za s polyangiitidou, mikroskopick? polyangiitida a eozinofiln? granulomat?za s polyangiitidou. Nej?ast?ji postihuj? org?ny ORL oblasti, pl?ce a ledviny. Stanoven? diagn?z...

  • Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies

    by Philipp Gauckler, Anna Matyjek, Seleni Kapsia, Smaragdi Marinaki, Luis F. Quintana, Montserrat M. Diaz, Catherine King, Siân Griffin, Raja Ramachandran, Balazs Odler, et al.

    Key Points: Fifty-five percent of patients achieve long-term remission after rituximab treatment. This is influenced by maintenance therapy with rituximab. A substantial reduction of annualized relapse rate and concomitant immunosuppression was observed after rituximab treatment. Background: Long-term outcomes of rituximab-treated adult patients with podocytopathies (either minimal change disease or FSGS) are largely unknown. Methods: A retrospective study at 30 nephrology departments from 15 countries worldwide included rituximab-treated adults with primary podocytopathies and a minimum clinical follow-up of 36 months. The primary outcome was relapse-free survival at 36 months. Results: One hundred eighty-three adult patients (n=64 with FSGS and n=119 with minimal change disease) with difficult-to-treat nephrotic syndrome (68% steroid-dependent/frequently relapsing, 22% steroid-resistant, 85% previously treated with two or more lines of immunosuppressive therapy) were treated with rituximab as part of a remission induction regimen. Complete or partial remission at 6 months after rituximab treatment was achieved in 82%. Eighty-three of 151 (55%) initial responders achieved long-term relapse-free survival over 3 years. Maintenance therapy with rituximab was associated with a better relapse-free survival (hazard ratio, 2.05; 95% confidence interval [CI], 1.07 to 3.91), irrespective of the dosing regimen. At 36 months, 61% of initial responders receiving maintenance therapy with rituximab achieved long-term relapse-free survival and withdrawal of all concomitant immunosuppressive medication compared with 36% of patients without maintenance treatment (odds ratio, 2.69; 95% CI, 1.27 to 5.73). Relapses per year were reduced from an annual relapse rate of 1.0 (95% CI, 1.0 to 1.7) before to 0.17 (95% CI, 0.00 to 0.24) relapses per year after rituximab initiation. Over the 36 months of follow-up, a stable course of eGFR was observed in those who initially responded with either complete or partial remission, whereas nonresponders experienced a reduction in eGFR reaching −11 (95% CI, −18 to −8) ml/min per 1.73 m2. Conclusions: Rituximab facilitated achievement of initial and long-term response in a majority of adult patients with difficult-to-treat podocytopathies. Maintenance treatment with rituximab was further associated with long-term relapse-free survival over 3 years. Nonresponse to initial rituximab treatment was associated with poor kidney prognosis.


  • Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy

    by Vojtech Kratky, Anna Valerianova, Zdenka Hruskova, Vladimir Tesar, Jan Malik

    Purpose of Review Chronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular disease (CVD). This review summarizes known risk factors, pathophysiological mechanisms, and current therapeutic possibilities, focusing on lipid-lowering therapy in CKD. Recent Findings Novel data on lipid-lowering therapy in CKD mainly stem from clinical trials and clinical studies. Summary In addition to traditional CVD risk factors, patients with CKD often present with non-traditional risk factors that include, e.g., anemia, proteinuria, or calcium-phosphate imbalance. Dyslipidemia remains an important contributing CVD risk factor in CKD, although the mechanisms involved differ from the general population. While statins are the most commonly used lipid-lowering therapy in CKD patients, some statins may require dose reduction. Importantly, statins showed diminished beneficial effect on cardiovascular events in patients with severe CKD and hypercholesterolemia despite high CVD risk and effective reduction of LDL cholesterol. Ezetimibe enables the reduction of the dose of statins and their putative toxicity and, in combination with statins, reduces CVD endpoints in CKD patients. The use of novel drugs such as PCSK9 inhibitors is safe in CKD, but their potential to reduce cardiovascular events in CKD needs to be elucidated in future studies.


  • Open Access

    Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying

    by Karl Gisslander, Matthew Rutherford, Louis Aslett, Neil Basu, François Dradin, Lucy Hederman, Zdenka Hruskova, Hicham Kardaoui, Peter Lamprecht, Sabina Lichołai, et al.

    Objectives This study aims to describe the data structure and harmonisation process, explore data quality and define characteristics, treatment, and outcomes of patients across six federated antineutrophil cytoplasmic antibody-associated vasculitis (AAV) registries. Methods Through creation of the vasculitis-specific Findable, Accessible, Interoperable, Reusable, VASCulitis ontology, we harmonised the registries and enabled semantic interoperability. We assessed data quality across the domains of uniqueness, consistency, completeness and correctness. Aggregated data were retrieved using the semantic query language SPARQL Protocol and Resource Description Framework Query Language (SPARQL) and outcome rates were assessed through random effects meta-analysis. Results A total of 5282 cases of AAV were identified. Uniqueness and data-type consistency were 100% across all assessed variables. Completeness and correctness varied from 49%–100% to 60%–100%, respectively. There were 2754 (52.1%) cases classified as granulomatosis with polyangiitis (GPA), 1580 (29.9%) as microscopic polyangiitis and 937 (17.7%) as eosinophilic GPA. The pattern of organ involvement included: lung in 3281 (65.1%), ear-nose-throat in 2860 (56.7%) and kidney in 2534 (50.2%). Intravenous cyclophosphamide was used as remission induction therapy in 982 (50.7%), rituximab in 505 (17.7%) and pulsed intravenous glucocorticoid use was highly variable (11%–91%). Overall mortality and incidence rates of end-stage kidney disease were 28.8 (95% CI 19.7 to 42.2) and 24.8 (95% CI 19.7 to 31.1) per 1000 patient-years, respectively. Conclusions In the largest reported AAV cohort-study, we federated patient registries using semantic web technologies and highlighted concerns about data quality. The comparison of patient characteristics, treatment and outcomes was hampered by heterogeneous recruitment settings.


  • Open Access

    Unique Biomarkers of Collagen Type III Remodeling Reflect Different Information Regarding Pathological Kidney Tissue Alterations in Patients with IgA Nephropathy

    by Nadja Sparding, Michaela Neprasova, Dita Maixnerova, Federica Genovese, Morten Asser Karsdal, Marek Kollar, Helena Koprivova, Zdenka Hruskova, Vladimir Tesar

    Kidney fibrosis is the hallmark of chronic kidney disease (CKD) and is characterized by an imbalanced extracellular matrix (ECM) remodeling. Collagen type III is one of the main ECM components of the interstitial matrix of the kidney. We hypothesized that measuring three biomarkers of collagen type III reflecting different aspects of this protein turnover (C3M, C3C, and PRO-C3) may provide different information about the fibrotic burden in patients with IgA nephropathy (IgAN). We examined a cohort of 134 patients with IgAN. The three collagen type III biomarkers were measured in serum (S) and in urine (U) samples taken on the same day before kidney biopsy was performed. Biopsies were evaluated for interstitial fibrosis and tubular atrophy, according to the Banff and MEST-C scores. S-PRO-C3 and S-C3C correlated with the degree of fibrosis in the biopsy, whereas U-C3M/Cr had an inverse correlation with fibrosis. U-C3M/Cr had the highest discrimination ability for advanced fibrosis, which was maintained after adjustment for the other collagen type III biomarkers, proteinuria, and serum creatinine. The data presented in this study indicate that measuring the different fragments of the same ECM protein and in different matrices provides a variety of information regarding pathological kidney tissue alterations in patients with IgAN.


  • Open Access

    Serum and Urine Biomarkers Related to Kidney Fibrosis Predict Kidney Outcome in Czech Patients with IgA Nephropathy

    by Michaela Neprasova, Dita Maixnerova, Nadja Sparding, Federica Genovese, Morten Asser Karsdal, Helena Koprivova, Marek Kollar, Miloslav Suchanek, Zdenka Hruskova, Vladimir Tesar

    We evaluated biomarkers related to kidney fibrosis for the outcome of patients with IgA nephropathy (IgAN). Clinical parameters (estimated glomerular filtration rate, hypertension, proteinuria) and histological findings were assessed in 134 patients with IgAN at the time of diagnosis and followed up prospectively (mean follow-up time, 56.5 months). We measured biomarkers of collagen and laminin turnover in serum and urine collected at the time of kidney biopsy using a novel enzyme-linked immunosorbent assay. Linear discriminant analysis and logistic regression models were used to predict the patient’s kidney outcome. Five serum and urine biomarkers of laminin and collagen turnover (sLG1M, sPRO-C3, sPRO-C6, uPRO-C6/Cr, uC3M/Cr) could significantly differentiae IgAN patients with a worse prognosis. Clinical parameters (glomerular filtration rate (GFR), proteinuria) distinguished patients at risk of IgAN progression with a specificity of 87.3% and a sensitivity of 45.2% (area under the curve-AUC 0.751). The addition of the biomarkers significantly increased the prognostic ability with a specificity of 85.1% and a sensitivity of 73.3% (AUC 0.905). We have identified three serum (sLG1M, sPRO-C3, sPRO-C6) and two urinary markers (uPRO-C6/Cr, u-C3M /Cr) that significantly improve the prognostic ability of markers of kidney function to identify an IgAN patient’s risk of progressing to ESKD.


  • Open Access

    Analysis of microRNAs in Small Urinary Extracellular Vesicles and Their Potential Roles in Pathogenesis of Renal ANCA-Associated Vasculitis

    by Jana Frydlova, Iveta Zednikova, Veronika Satrapova, Eva Pazourkova, Sarka Santorova, Zdenka Hruskova, Vladimir Tesar, Martin Vokurka, Petr Prikryl, Marie Korabecna

    Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) represents an autoimmunity disease characterized by high mortality. For successful treatment, the detailed knowledge of its complex pathogenesis and the set of biomarkers for differential diagnostics are desired. Analysis of molecular content of small urinary extracellular vesicles (uEV) offers the possibility to find markers in the form of microRNAs (miRNAs) and study the pathways involved in pathogenesis. We used next-generation sequencing in the first preliminary study to detect the miRNAs with altered expression in uEVs of patients with AAV in comparison with age-matched controls. We confirmed the results using single-target quantitative polymerase chain reaction tests on different sets of samples and found five miRNAs (miR-30a-5p, miR-31-3p, miR-99a-5p, miR-106b-5p, miR-182-5p) with highly elevated levels in uEVs of patients. We performed the comparison of their targets with the differentially expressed proteins in uEVs of patients included in the first phase. We realized that upregulated miRNAs and proteins in uEVs in AAV patients target different biological pathways. The only overlap was detected in pathways regulating the actin cytoskeleton assembly and thus potentially affecting the glomerular functions. The associations of upregulated miRNAs with pathways that were neglected as components of complex AAV pathogenesis, e.g., the epidermal growth factor receptor signaling pathway, were found.


  • Open Access

    Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients

    by Anna Valerianova, Jan Malik, Jana Janeckova, Lucie Kovarova, Vladimir Tuka, Pavel Trachta, Jana Lachmanova, Zuzana Hladinova, Zdenka Hruskova, Vladimir Tesar